Concepedia

Julie A. Laxer

JA

Statistics

Publications

7

Citations

933

H-Index

7

Active since

1989

Affiliations

Response Technologies (United States)(Current)

Response Biomedical (Canada)

University of California San Diego Medical Center

Julie A. Laxer is an author at Response Technologies (United States) specializing in immunology, life sciences, and t cell biology.

Publications per year

1989–1997

7

Publications

7

A new murine CD4+ T cell subset with an unrestricted cytokine profile.

Gary S. Firestein, W Roeder, Julie A. Laxer et al. · The Journal of Immunology · 1989 · 365 citations

, , +17

CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes.

Jennie C.C. Chang, Larry Smith, Karen Froning et al. · Proceedings of the National Academy of Sciences · 1994 · 233 citations · Full text

, , +17

The Cytotoxic Effects of Commonly Used Topical Antimicrobial Agents on Human Fibroblasts and Keratinocytes

Matthew Cooper, Julie A. Laxer, John F. Hansbrough · The Journal of Trauma: Injury, Infection, and Critical Care · 1991 · 196 citations

, , +11

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide

Daniel P. Gold, Richard Smith, Anna B. Golding et al. · Journal of Neuroimmunology · 1997 · 57 citations

, , +16

CD8<sup>+</sup> T‐Cells in Psoriatic Lesions Preferentially Use T‐Cell Receptors Vβ3 and/or Vβ13.1 Genes

Jennie C.C. Chang, Lawrence R. Smith, Karen Froning et al. · Annals of the New York Academy of Sciences · 1995 · 56 citations

, , +17

1–5 of 7